Association between the receptor for advanced glycation end products gene polymorphisms and coronary artery disease.

Receptor for advanced glycation end products (RAGE) is a cell-surface molecule member of the immunoglobulin superfamily and thought to play a critical role in diabetic atherosclerosis. A growing body of studies has been conducted to determine the extent to which the variants of RAGE gene influence the risk of coronary artery disease (CAD). However, these have reported conflicting results. To investigate this inconsistency, we performed a comprehensive meta-analysis on the associations between the RAGE -374T/A, -429T/C, and Gly82Ser polymorphisms and the risk of CAD. A total of 4,402 cases and 6,081 controls from 17 published case-control studies were included. The overall odds ratio (OR) of CAD was 0.99 (95 % CI 0.87-1.13), 1.06 (95 % CI 0.95-1.18) and 1.12 (95 % CI 0.90-1.39) for -374A, -429C, and the minor S allele of the Gly82Ser polymorphism, respectively. Similarly, no significant results were observed for these polymorphisms using dominant model. However, when stratified by diabetic/non-diabetic status of the CAD patients, we found significant association among Caucasian type two diabetic CAD patients with the -374A allele [OR 1.39, 95 % CI 1.10-1.76, P(Z) = 0.006], while no association was detected between the -374T/A polymorphism and non-diabetic CAD in Caucasians [OR 0.79, 95 % CI 0.58-1.07, P(Z) = 0.13]. In conclusion, this meta-analysis suggested that possession of the -374A allele may be a risk factor in CAD among Caucasian patients with type two diabetes.